
A rare, simultaneous surge in IPOs, QIPs, and block deals is set to propel India Inc's market mop-up to an all-time high in FY27 as pragmatic pricing accelerates deal execution, said Amit Ramchandani, head of investment banking at Motilal Oswal.


Torrent Pharma reports a 26% net profit decline despite 42% revenue growth, while planning a ₹5,000 crore QIP.